PDE4B Inhibitors For Treating Major Depression

描述（由申请人提供）：Tetra Discovery Partners计划开发一种基于磷酸二酯酶4 B（PDE 4 B）抑制的重度抑郁症新疗法。独特的是，Tetra药物将解决炎症作为抑郁症的一个因素。这是一种新的抗抑郁药物的作用机制，应该证明是对当前治疗方法的补充。解决炎症将针对目前无法治疗的患者，例如接受干扰素-a（IFNa）治疗病毒性疾病的患者，患有银屑病合并症的抑郁患者，炎症性肠病，创伤性脑损伤或创伤后应激障碍。鉴于目前治疗的局限性，需要具有新作用机制的新药物。重度抑郁症的患病率是惊人的，大约20%的人在生活中的某个时候经历过抑郁症。该公司估计，10-20%的抑郁症患者患有炎症，将是Tetra药物的理想候选人。到2018年，抗抑郁药物市场预计将以3.2%的复合年增长率增长至109亿美元。世界卫生组织预测，到2020年，抑郁症将与心脏病竞争，成为世界上疾病负担最高的健康障碍。第二阶段SBIR项目将完成用于人类的PDE 4 B抑制剂的化学优化，以及向美国食品药品监督管理局（FDA）提交研究性新药（IND）申请所需的临床前安全性和毒性研究，用于重度抑郁症的人体临床试验。

DESCRIPTION (provided by applicant): Tetra Discovery Partners proposes to develop a new treatment for major depressive disorder based on inhibition of phosphodiesterase 4B (PDE4B). Uniquely, the Tetra drug will address inflammation as a contributor to depression. This is a new mechanism of action for an antidepressant drug which should prove complimentary to current therapeutics. Addressing inflammation will target currently untreatable patients, such as those receiving interferon-a (IFNa) for viral illness, depressed patients with co-morbid psoriasis, inflammatory bowel disease, traumatic brain injury, or post-traumatic stress disorder. Given the limitations of current treatments, there is a need for new medications with novel mechanisms of action. The prevalence of major depression is staggering with around 20% of people experiencing depression at some point in their lives. The company estimates that 10-20% of patients with depression have inflammation and will be ideal candidates for the Tetra drug. The market for antidepressant drugs is expected to grow at a CAGR of 3.2% to US $10.9 billion by 2018. The World Health Organization predicts that by 2020, depression will rival heart disease as the health disorder with the highest disease burden in the world. The Phase II SBIR project will complete chemical optimization of a PDE4B inhibitor for use in human and the preclinical safety and toxicity studies needed for filing an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for human clinical trials in major depression.